Prognosis and chemotherapy efficacy in small-tumor breast cancer with different immune subtypes: a SEER-based study
Hong Mei Wang, Yue Hui Zhou, Gu Bin Lin, Bi Lian Zheng, Kun Zhang, Xiu Rong Chi, Yi Peng, Xiao Xi Huang, Hua Le Zhang · 2025
Read Prognosis and chemotherapy efficacy in small-tumor breast cancer with different immune subtypes: a SEER-based study by Hong Mei Wang, Yue Hui Zhou, Gu Bin Lin, Bi Lian Zheng, Kun Zhang, Xiu Rong Chi, Yi Peng, Xiao Xi Huang, Hua Le Zhang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12776230.txt.
Description
Hong Mei Wang and co-authors study survival and chemotherapy benefit in small breast tumors, split by immune type and node spread, in work from 2025. Small tumors can still behave very differently once nodes are involved. Prior work rarely split these patients finely by both traits.
Records came from a large United States cancer registry. Survival models weighed stage, node count, and immune type together. One mid-size stage with heavy node spread carried the worst death risk. Among early node cases, certain hormone and growth-factor types fared worst. Chemo after surgery helped survival in defined groups. The authors call for treatment plans tuned to subtype and stage, not size alone.
Catalog record
| CREATOR | Hong Mei Wang, Yue Hui Zhou, Gu Bin Lin, Bi Lian Zheng, Kun Zhang, Xiu Rong Chi, Yi Peng, Xiao Xi Huang, Hua Le Zhang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |